CoChat

Enhanced cross‐priming of naive CD 8+T cells by dendritic cells treated by the IM iDs® immunomodulatory compounds lenalidomide and pomalidomide

Open access
Henry, Jake Y., Labarthe, Marie‐Christine, Meyer, Brendan, Dasgupta, Prokar, Dalgleish, Angus G., Galustian, Christine · 2013 · Immunology
Cited by 85

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Summary: The IM i D s® immunomodulatory compounds lenalidomide and pomalidomide are agents with anti‐inflammatory, immunomodulatory and anti‐cancer activity. An excellent success rate has been shown for multiple myeloma in phase I/II clinical trials leading to F ood and D rug A dministration approval of lenalidomide. One mechanism by which these drugs could enhance anti‐tumour immunity may be through enhanced dendritic cell (DC) function. Thalidomide, a compound structurally related to lenalidomide and pomalidomide, is known to enhance DC function, and we have investigated whether its analogues, pomalidomide and lenalidomide, also have functional effects on DC s. We used mouse bone marrow‐derived DC s treated with 5 or 10 μ m pomalidomide, or lenalidomide from day 1 of culture. Treatment with IM i D® immunomodulatory compounds increased expression of C lass I (H 2‐K b), CD 86, and pomalidomide also increased C lass II (I‐A b) expression in bone marrow‐derived DC s, as measured by flow cytometry. Fluorescent bead uptake was increased by up to 45% when DC s were treated with 5 or 10 μ m pomalidomide or lenalidomide compared with non‐treated DC s. Antigen presentation assays using DC s primed with ovalbumin, and syngeneic T cells from transgenic OTI and OTII mice (containing MHC restricted, ovalbumin‐specific, T cells) showed that both pomalidomide and lenalidomide effectively increased CD 8+ T‐cell cross‐priming (by up to 47%) and that pomalidomide alone was effective in increasing CD 4+ T‐cell priming (by 30%). Our observations suggest that pomalidomide and lenalidomide enhance tumour antigen uptake by DC s with an increased efficacy of antigen presentation, indicating a possible use of these drugs in DC vaccine therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/imm.12087

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

Metadata

Authors
Henry, J. Y., Labarthe, M., Meyer, B., Dasgupta, P., Dalgleish, A. G., & Galustian, C.
Venue
Immunology
Publisher
Wiley
Published
2013-06-13
Volume
139
Issue
3
Pages
377-385
ISSN
  • 0019-2805 (ISSN-L)
  • 1365-2567
OpenAlex
W2033671876
Cited by
85
References
1
FWCI
4.88
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.